Kangning Jerry Pharmaceuticals - B (09966.HK) announced that it has entered into a licensing agreement with cspc pharma (01093.HK). Accordingly, cspc pharma obtains the exclusive license and sub-license rights in mainland China for the development, sales, promised sales, and commercialization of JSKN003 (used for the treatment of tumor-related indications), and becomes the only listed holder of the market approval for JSKN003 in that region. The company has the right to receive a total of up to 3.08 billion RMB in prepayment and milestone payments.
康寧傑瑞(09966.HK)向石藥(01093.HK)授出JSKN003內地獨家許可權
Corning Jerry (09966.HK) granted exclusive mainland license JSKN003 to Sino Pharmaceutical (01093.HK).
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.